AU3630297A - Galanin - Google Patents

Galanin

Info

Publication number
AU3630297A
AU3630297A AU36302/97A AU3630297A AU3630297A AU 3630297 A AU3630297 A AU 3630297A AU 36302/97 A AU36302/97 A AU 36302/97A AU 3630297 A AU3630297 A AU 3630297A AU 3630297 A AU3630297 A AU 3630297A
Authority
AU
Australia
Prior art keywords
galanin
treatment
supression
pain
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU36302/97A
Inventor
David Wynick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9615551.0A external-priority patent/GB9615551D0/en
Priority claimed from GBGB9623869.6A external-priority patent/GB9623869D0/en
Application filed by University of Bristol filed Critical University of Bristol
Publication of AU3630297A publication Critical patent/AU3630297A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)

Abstract

This invention relates to galanin and its uses. In particular, the invention provides a knockout mouse which lacks a functional galanin gene. The mouse may be used to investigate the effects of galanin. <??>It has also been unexpectedly discovered that galanin antagonists may be used in the management of pain, particularly painful neuropathies, the supression of pain, in the supression of location, in the treatment of prolactinoma and in anaesthesia. Additionally, the use of galanin agonists may be used in the treatment of Alzheimer's disease, in improving memory and cognition and in the treatment of nerve damage, such as the promotion of nerve regeneration.
AU36302/97A 1996-07-24 1997-07-24 Galanin Abandoned AU3630297A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9615551.0A GB9615551D0 (en) 1996-07-24 1996-07-24 Galanin
GB9615551 1996-07-24
GBGB9623869.6A GB9623869D0 (en) 1996-11-15 1996-11-15 Galanin
GB9623869 1996-11-15
PCT/GB1997/001991 WO1998003059A1 (en) 1996-07-24 1997-07-24 Galanin

Publications (1)

Publication Number Publication Date
AU3630297A true AU3630297A (en) 1998-02-10

Family

ID=26309752

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36302/97A Abandoned AU3630297A (en) 1996-07-24 1997-07-24 Galanin

Country Status (11)

Country Link
US (1) US20030009777A1 (en)
EP (2) EP1342410B1 (en)
JP (1) JP2000516212A (en)
AT (2) ATE457125T1 (en)
AU (1) AU3630297A (en)
DE (2) DE69721005T2 (en)
DK (2) DK1342410T3 (en)
ES (2) ES2340984T3 (en)
GB (1) GB2331301C (en)
PT (2) PT1342410E (en)
WO (1) WO1998003059A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU730137B2 (en) 1996-01-24 2001-03-01 H. Lundbeck A/S DNA encoding galanin GALR2 receptors and uses thereof
US6329197B2 (en) 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
US20030092042A1 (en) * 2001-08-27 2003-05-15 David Mu Amplified oncogenes and their involvement in cancer
WO2003070950A1 (en) * 2002-02-22 2003-08-28 Takeda Chemical Industries, Ltd. Novel dna and use thereof
GB0403509D0 (en) * 2004-02-17 2004-03-24 Neuro Targets Ltd Galanin receptors and brain injury
CA2580690A1 (en) * 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
AU2008207287A1 (en) * 2007-01-19 2008-07-24 Howard Florey Institute Of Experimental Physiology And Medicine Use of galanin in a method of treating neurodegenerative diseases or conditions
CA2699113A1 (en) * 2007-09-11 2009-04-09 Dorian Bevec Use of a peptide as a therapeutic agent
EP2187946A1 (en) * 2008-09-09 2010-05-26 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
ES2883838A1 (en) * 2020-06-04 2021-12-09 Univ Malaga PREVENTION AND/OR TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH DEMENTIA SYNDROMES (Machine-translation by Google Translate, not legally binding)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012997A1 (en) * 1991-01-16 1992-08-06 The General Hospital Corporation Human galanin
AU1462692A (en) * 1991-02-25 1992-09-15 Board Of Regents Of The University Of Washington, The Methods for detecting galanin antagonists
DE69225706T2 (en) * 1991-03-06 1998-11-26 Garvan Institute Of Medical Research, Darlinghurst, Neu Sued Wales/New South Wales HUMANES GALANINE, CDNA CLONES THAT ENCODE HUMANES GALANINE AND MAKE A METHOD OF HUMAN GALAMINE
SE9101472D0 (en) * 1991-05-15 1991-05-15 Trion Forskning & Utveckling GALANIN ANTAGONIST
JPH06172387A (en) * 1992-12-11 1994-06-21 Aibaitsu Kk Synthetic peptide derivative
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
AU730137B2 (en) * 1996-01-24 2001-03-01 H. Lundbeck A/S DNA encoding galanin GALR2 receptors and uses thereof

Also Published As

Publication number Publication date
US20030009777A1 (en) 2003-01-09
ES2196349T3 (en) 2003-12-16
DE69721005T2 (en) 2004-06-09
PT1342410E (en) 2010-05-11
GB9901264D0 (en) 1999-03-10
EP0918455A1 (en) 1999-06-02
ATE457125T1 (en) 2010-02-15
GB2331301C (en) 2005-05-22
ES2340984T3 (en) 2010-06-14
DE69739760D1 (en) 2010-03-25
EP1342410B1 (en) 2010-02-10
PT918455E (en) 2003-09-30
GB2331301A (en) 1999-05-19
DE69721005D1 (en) 2003-05-22
EP1342410A2 (en) 2003-09-10
DK1342410T3 (en) 2010-05-31
JP2000516212A (en) 2000-12-05
EP1342410A3 (en) 2003-12-10
WO1998003059A1 (en) 1998-01-29
GB2331301B (en) 2001-02-14
EP0918455B1 (en) 2003-04-16
DK0918455T3 (en) 2003-08-04
ATE237346T1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
EP1426375A3 (en) Analgesic spiroindole derivatives
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
BR9811780A (en) Bone volume increase method using non-naturally occurring selective fp agonists
BG105256A (en) Muscarinic agonists and antagonists
GB2331301B (en) Galanin
EP1178988A4 (en) Compounds and therapeutic methods
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
AU2002311556A1 (en) Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere&#39;s disease
WO2001015677A3 (en) Use of 5-ht1b/1d agonists to treat otic pain
WO2001080894A3 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
AU2434297A (en) The use of 5-ht1b/1d agonists to treat ocular pain
WO2000051585A3 (en) Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
AU2002348324A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 46566
AU2002357691A1 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
WO2000051577A3 (en) Use of fluorinated triazoles for treating pain and affective or attention disorders
MXPA02004704A (en) Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders.
UA33242A (en) Device for fixation and treatment of renal grafts
EP0663211A4 (en) Agent for preventing and treating digestive mucosal disorders.